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ABSTRACT
Among 5938 clinical Shigella spp. isolates, two S. flexneri strains were isolated as those resistant to
fluoroquinolones based on the MICs of the following antibiotics: ciprofloxacin, norfloxacin, ofloxacin,
sparfloxacin and levofloxacin. S. flexneri 021787 had three substitutions, one in GyrA (Ser83Leu) and two
in ParC (Ser80Ile and Arg91Gln). S. flexneri 021895 had four substitutions, two in GyrA (Ser83Leu and
Asp87Gly) and two in ParC (Ser80Ile and Arg91Gln). The increased susceptibility of S. flexneri 021787
and S. flexneri 021895 to ciprofloxacin, norfloxacin and ofloxacin in the presence of the uncoupler
carbonyl cyamide-m-chlorophenyldrazone implied that energy-dependent active efflux pumps contrib-
uted to the resistance against fluoroquinolones. Both S. flexneri 021787 and S. flexneri 021895 were also
induced to express tolC (encoding a resistance–nodulation–division transporter), mdfA (encoding a
major facilitator superfamily transporter), and ydhE (encoding a multidrug and toxic compound
extrusion transporter) in the presence of ciprofloxacin. Thus, these results indicated that chromosome-
mediated fluoroquinolone resistance of S. flexneri 021787 and S. flexneri 021895 resulted from the
combination of target site mutations and enhanced expression of genes encoding efflux pumps.
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INTRODUCTION
Since 1998 there has been a steady increase in
Korea of the human disease shigellosis,caused by
Shigella sonnei and S. flexneri. Although appropri-
ate antibiotic therapy may reduce the duration of
symptoms and excretion of Shigella, it may also
increase the risk of developing antibiotic-resistant
strains [1]. The antibiotics most commonly used
for the treatment of shigellosis in Korea are
ceftriaxone, trimethoprim–sulphamethoxazole
and ciprofloxacin. The isolation of S. sonnei strains
producing extended-spectrum b-lactamases was
reported previously [2], and their reduced
susceptibility to fluoroquinolones, which resulted
in an increased emergence of quinolone-resistant
Shigella in Korea, was confirmed.
Resistance to fluoroquinolones in Gram-nega-
tive organisms is usually caused by one of two
mechanisms. One mechanism is a result of muta-
tions in the target genes of fluoroquinolone, gyrA
and gyrB (encoding DNA gyrase), and parC and
parE (encoding topoisomerase IV) [3]. The second
mechanism is the result of the active efflux of
fluoroquinolone.
Efflux pumps for fluoroquinolonones in Gram-
negative bacteria have been grouped into three
superfamilies on the basis of amino acid sequence
homology, and include the resistance–nodula-
tion–division (RND) family, the major facilitator
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superfamily (MFS), and the multidrug and toxic
compound extrusion (MATE) family [4]. Efflux-
mediated resistance to fluoroquinolones has been
reported in a number of pathogenic Gram-nega-
tive bacteria, including Escherichia coli, Salmonella
typhimurium, Serratia marcescens and Vibrio cholerae
[5]. It has also been reported that fluoroquinolone
resistance is often the result of a combination of
target site mutations and enhanced expression of
genes encoding efflux pumps in resistant bacteria
[5–7].
In the genus Shigella, an efflux pump for
fluoroquinolones has been shown to confer a
high level of quinolone resistance to S. dysenteriae
[8]. However, in the other Shigella spp., only
orthologues of the RND family were identified
during a genomic BLAST search of S. flexneri [4].
In this study, the mechanism of chromosome-
mediated fluoroquinolone resistance in S. flexneri
isolates, which results from the combination of
target site mutations and the enhanced expression
of genes for efflux pumps, has been determined.
MATERIALS AND METHODS
Bacterial isolates
From 1998 to 2002, 5938 clinical Shigella spp. isolates were
obtained from the national public health network of Korea. The
antibiotic susceptibility of these isolateswas determined using a
disk diffusion test. Seven S. sonnei isolates and six S. flexneri
isolates demonstrated fluoroquinolone resistance, and their
inhibitory zone was less than or close to the intermediate range
(<24 mm) as determined by the CLSI criteria [7].
Determination of MICs
The MICs of fluoroquinolones were determined on Mueller–
Hinton agar (Becton Dickinson, Franklin Lakes, MA, USA)
using an agar dilution method (the CLSI method) with a
final inoculum size of 104 CFU ⁄ spot [9]. E. coli ATCC 25922
was used as a control for quality assurance [1,9]. Antibiotics
were obtained from the following sources: ciprofloxacin,
norfloxacin (Sigma, St. Louis, MO, USA), ofloxacin (Sigma),
sparfloxacin (Sam-A Pharm. Co., Seoul, Korea), and levo-
floxacin (Kuk-Jei Pharm. Co., Seongnam, Korea). The CLSI
criteria were used to categorize strains as susceptible,
intermediate or antibiotic-resistant [9].
DNA sequence analysis of the quinolone resistance-
determining region (QRDR)
The QRDRs of gyrA, gyrB, parC and parE were amplified by
PCR [10], and sequenced using an ABI 3700 sequencer
(Applied Biosystems, Foster City, CA, USA). These portions
of the QRDR corresponded to amino acid residues 54–171 of
GyrA, 397–520 of GyrB, 12–130 of ParC, and 421–524 of
ParE.
Amplification of qnrA, qnrB, qnrS and aac(6¢)-Ib-cr
Primers suitable for multiplex PCR targeting qnrA, qnrB,
qnrS and aac(6¢)-Ib-cr were designed using PRIMER EXPRESS
v. 2.0 (Applied Biosystems, Foster City, CA, USA) and
synthesized by Bioneer Co. (Daejeon, Korea). The primer
sets used in this study are listed in Table 1. The PCR was
performed in a final volume of 25 lL containing 2 lL of
template DNA, 1· reaction buffer, 0.2 mM each deoxynu-
cleoside triphosphate, 20 pM each primer, and 3.5 units of
Taq polymerase. The assays were performed in a Peltier
Thermal Cycler (MJ Research, Waltham, MA, USA) under the
following conditions: one cycle at 94C for 5 min followed by 30
cycles at 94C for 1 min, 60C for 1 min and 72C for 1 min and
a final extension at 72C for 5 min.
Synergy tests
Synergy tests were performed using the fluoroquinolones
ciprofloxacin, norfloxacin, and ofloxacin, and the efflux
pump inhibitor carbonyl cyamide-m-chlorophenyldrazone
(CCCP). CCCP was added to the Mueller–Hinton agar at a
concentration of 100 lM. Susceptibility testing for cipro-
floxacin, norfloxacin and ofloxacin by agar dilution was
performed in agar plates, both with and without CCCP
[11,12].
Expression of mdfA, tolC and ydhE
Isolates were cultured in 5 mL of Mueller–Hinton broth, with
or without 0.2 mg ⁄L of ciprofloxacin, at 37C for 30 min. Total
RNA was isolated using the RNeasy Mini kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s protocol.
Complementary DNA (cDNA) synthesis was performed in a
final volume of 20 lL containing 3 lL of total RNA, 200 units
of M-MLV reverse transcriptase (Invitrogen, Carlsbad, CA,
USA), 4 lL of 5· first standard buffer, 1 lL of 10 mM dNTP,
1 lL of RNaseOUT, 2 lL of 0.1 M dithiothreitol, and 1 lL of
random primer (Invitrogen), following the manufacturer’s
protocol. The synthesis conditions included an initial incuba-
tion at 37C for 2 min, followed by an incubation at 42C for
45 min. Reactions were inactivated by heating at 70C for
Table 1. Primers used in this study
Target gene Primer Sequence (5¢ ﬁ 3¢)
tolC RtolC F CAGACCGATCAGCAAACCTTGA
RtolC R GCCTGTGTATAGGAAAGAACGTCAA
Probe FAM-CCGCGACCGCTTATT-5 NFQ
mdfA RmdfA F GGCTGGCCGATTATGATTGGT
RmdfA R CGCGTGCGATGAGATAACC
Probe FAM-CAGCAGCGACCAATAG-5NFQ
ydhE RydhE F CCGGCGATCCTCTTTGGT
RydhE R GGAACCATTTAATTGCGCGATAACC
Probe FAM-CTGCTGGCATTAACG-5 NFQ
16S rRNA R16S rRNA F CCCCCTGGACGAAGACTGA
R16S rRNA R GTGGACTACCAGGGTATCTAATCCT
Probe FAM-TCCCCACGCTTTCG-5 NFQ
qnrA qnrA F AGAGGATTTCTCACGCCAGGA
qnrA R TTGAGATCGCACTCCCTGAA
qnrB qnrB F GGCTGGCCGATTATGATTGGT
qnrB R CGCGTGCGATGAGATAACC
qnrS qnrS F TGCCACTTTGATGTCGCAGAT
qnrS R CGCACGGAACTCTATACCGTAG
aac(6¢)-Ib-cr aac(6¢)-Ib-cr F ATCTCATATCGTCGAGTGGTGG
aac(6¢)-Ib-cr R CGCTTTCTCGTAGCATCGGAT
FAM, 6-Carboxfluorescein; 5 NFQ, 5 Non-fluorescent quencher.
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15 min [13]. The corresponding expression level of each gene,
relative to a 16S rRNA reference, was determined using an ABI
Prism 7900HT sequence detection system (Applied Biosys-
tems). Quantification PCR reactions were prepared in a final
volume of 20 lL containing 2.5 mL of cDNA with TaqMan
One-Step RT-PCR master mix (Applied Biosystems). The
primer sets used for this study are listed in Table 1.
The cycling conditions were 40 cycles at 95C for 15 s,
followed by 60C for 1 min. Quantification was based on the
threshold cycle value, which was determined with the aid
of the SDS 2.1 software system (Applied Biosystems). Relative
gene expression levels were calculated as 2 – DDCT, where
DDCT = DCT(sample) ) DCT(control), and DCT is the CT
(threshold cycle) of the target gene subtracted from the CT of
the housekeeping gene [14]. All tests were repeated five times,
and the relative gene expression value indicated is the average
of the results of these tests.
RESULTS
Susceptibility of Shigella isolates to
fluoroquinolones
Two S. flexneri isolates, 021787 and 021895, were
found to be resistant to the fluoroquinolones
tested: ciprofloxacin (MIC, 8–16 mg ⁄L), norfloxa-
cin (MIC, 32 mg ⁄L), ofloxacin (MIC, 8–32 mg ⁄L),
sparfloxacin (MIC, 16–32 mg ⁄L), and levofloxacin
(MIC, 16 mg ⁄L). The other 11 isolates were found
to be susceptible to fluoroquinolones, on the basis
of CLSI criteria (Table 2).
Mutations in gyrA, gyrB, parC and parE
According to the sequence analysis of the
quinolone resistance-related genes, there were
no alterations in the amino acids in GyrB and
ParE, whereas several mutations were detected in
GyrA and ParC. The S. sonnei isolates 982962,
994263, 000207, 013008, 020065 and 020369, as well
as the S. flexneri isolates 990379 and 000784, had
only one mutation in GyrA (Ser83(TCG) ﬁ Le-
u(TTG)). No other mutations in these isolates
were observed in GyrB, ParC or ParE. In S. flexneri
990036 and S. flexneri 022149, and S. sonnei
021586, Arg91(CGA) in ParC was replaced by
Gln(CAG). No other mutations in these isolates
were found in GyrA, GyrB or ParC (Table 2).
Isolates with a single mutation in either GyrA or
ParC were categorized as susceptible to fluoroqu-
inolones. However, fluoroquinolone-resistant iso-
lates of S. flexneri, 021787 and 021895, were
observed to have multiple mutations in gyrA
and parC. S. flexneri 021787 contained three sub-
stitutions, one in GyrA (Ser83Leu), and two in
ParC (Ser80Ile and Arg91Gln). S. flexneri 021895
exhibited four substitutions, two in GyrA (Ser83-
Leu and Asp87Gly) and two in ParC (Ser80Ile and
Arg91Gln).
Involvement of putative efflux pumps in
fluoroquinolone resistance
To elucidate the involvement of efflux pumps in
fluoroquinolone resistance in Shigella isolates,
synergy experiments were performed using the
efflux pump inhibitor CCCP and the fluoroqui-
nolones ciprofloxacin, norfloxacin and ofloxacin.
A degree of synergy between CCCP and fluor-
oquinolones was observed using the agar dilution
Table 2. MICs and nucleotide changes in the quinolone resistance-determining regions of gyrA and parC of different
Shigella sonnei and Shigella flexneri isolates
Yeara Strain no. Species
MIC (mg ⁄L)
gyrA amino acid at
codon









83 87 80 91
TCG(Ser) GAC(Asp) AGC(Ser) CGA(Arg)
1998 982962 S. sonnei 1.0 0.5 4 2 2 2 1 1 -T(Leu) – – –
1999 994263 S. sonnei 0.125 0.125 0.5 0.25 0.5 0.5 0.25 0.25 -T(Leu) – – –
1999 990036 S. flexneri 0.5 0.125 0.5 0.25 1 1 2 1 – – – -AG(Gln)
1999 990379 S. flexneri 0.25 0.25 0.5 0.5 0.5 0.5 0.25 0.25 -T(Leu) – – –
2000 000207 S. sonnei 0.25 0.125 0.5 0.25 0.5 0.5 0.25 0.25 -T(Leu) – – –
2000 000784 S. flexneri 0.125 0.125 0.5 0.25 0.5 0.5 0.25 0.25 -T(Leu) – – –
2001 013008 S. sonnei 0.25 0.125 0.5 0.25 0.5 0.5 0.25 0.5 -T(Leu) – – –
2002 020065 S. sonnei 0.25 0.125 0.5 0.25 0.5 0.5 0.5 0.5 -T(Leu) – – –
2002 021586 S. sonnei 0.5 0.25 0.5 0.5 1 0.5 1 0.5 – – – -AG(Gln)
2002 020369 S. sonnei 0.5 0.25 0.5 0.5 1 1 1 0.5 -T(Leu) – – –
2002 021787 S. flexneri 16 0.125 32 0.25 32 0.25 32 16 -T(Leu) – -T(Ile) -AG(Gln)
2002 021895 S. flexneri 8 0.125 32 0.25 8 0.25 16 12 -T(Leu) -G(Gly) -T(Ile) -AG(Gln)
2002 022149 S. flexneri 0.5 0.25 1 0.25 1 0.5 2 0.5 – – – -AG(Gln)
Each value is the average of six replicates.
aYear of isolation.
CIP, ciprofloxacin; NOR, norfloxacin; OFX, ofloxacin; SPX, sparfloxacin; LVX, levofloxacin; CCCP, carbonyl cyamide-m-chlorophenyldrazone.
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method. The MICs of fluoroquinolones for S. flex-
neri 021787 and S. flexneri 021895 were decreased
32-fold to 128-fold in an agar plate containing
CCCP when compared to those observed
in CCCP-free medium (Table 2). After addition
of CCCP, the MICs for S. flexneri 021787 and
S. flexneri 021895 reverted to levels almost equiv-
alent to those for S. flexneri 000784, which con-
tained a single substitution in GyrA (Ser83Leu).
Efflux pumps did not seem to be involved in the
resistance of S. flexneri 990379 to fluoroquinol-
ones, because there was no change in MICs in the
presence or absence of CCCP.
Expression of the efflux pump-encoding genes
mdfA, tolC and ydhE
Real-time PCR showed that S. flexneri 021787 and
S. flexneri 021895 exhibited 1.8–2.4 times higher
expression of tolC and a similar heightened
expression of mdhA and ydhE relative to the
control isolate S. flexneri 990379, in the absence of
ciprofloxacin (Fig. 1). However, when ciprofloxa-
cin was added to the medium, the expression of
all three genes increased in both S. flexneri 021787
and S. flexneri 021895. S. flexneri 021787 expressed
5.14 times more mdfA, 3.95 times more tolC and
2.7 times more ydhE than the control isolate.
S. flexneri 021895 expressed 3.07 times more mdfA,
2.07 times more tolC and 2.53 times more ydhE
than the control isolate.
Presence of plasmid-borne quinolone resistance
genes qnrA, qnrB, qnrS and aac(6¢)-Ib-cr
Among the possible plasmid-borne quinolone
resistance genes, qnrS was the only gene found
in both S. flexneri 021787 and S. flexneri 021895
(data not shown).
DISCUSSION
Resistance to quinolones is usually due to muta-
tions in the bacterial targets DNA gyrase and
topoisomerase IV, or due to an activation of
efflux pumps. Thirteen clinical isolates with
reduced susceptibility to fluoroquinolones were
examined to locate mutations in gyrA and parC.
The mutation at the codon specifying Ser83 in
GyrA, which produced a change to leucine,
occurred in eight of the 13 isolates and conferred
reduced susceptibility. GyrA contains the QRDR
near the active site, between codons 67 and 106
[15,16]. Thus, the change of the polar amino acid
serine to a hydrophobic leucine or isoleucine may
alter the target structure and render it less
susceptible to fluoroquinolones [17,18]. A single
substitution of arginine for glutamine at posi-
tion 91 in ParC occurred in two of the 13 isolates
and also conferred reduced susceptibility to flu-
oroquinolones [19]. A mutation of a charged
amino acid to a non-charged polar amino acid
may cause a change in either the target structure
or its drug-binding strength, which would result
in less susceptibility to quinolones. A single
mutation at position 83 in GyrA and double
mutations at positions 80 and 91 in ParC occurred
in S. flexneri 021787. Double mutations at posi-
tion 83 in GyrA and double mutations at posi-
tions 80 and 91 in ParC also occurred in S. flexneri
021895. In general, reduced susceptibility due to a
change of Ser83 in GyrA can be followed by an
increase in resistance with the addition of one or
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Fig. 1. Expression of tolC, mdfA and ydhE, measured by RT-PCR in the absence and presence of ciprofloxacin. Each value is
the average of five culture replicates, each of which was evaluated twice. Relative gene expression levels were calculated as
2 – DDCT, where DDCT = DCT(sample) ) DCT(control)
3. CT: threshold cycle.
Strains: 379, Shigella flexneri 990379; 1787, S. flexneri 021787; 1895, S. flexneri 021895;
()), absence of ciprofloxacin; +, presence of ciprofloxacin.
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mutations in GyrA in S. flexneri 021895 were not
associated with higher levels of resistance relative
to a single GyrA mutation in S. flexneri 021787.
Efflux pumps utilize the energy of the proton-
motive force to transport antibiotics out of the cell
[21,22]. Increased susceptibility of S. flexneri
021787 and S. flexneri 021895 to ciprofloxacin,
norfloxacin and ofloxacin in the presence of the
uncoupler CCCP implied selective drug extrusion
by an energy-dependent active efflux pump. After
the addition of CCCP, the accumulation of cipro-
floxacin, norfloxacin and ofloxacin could have
increased, and thus led to lower MICs for both
isolates. Inhibition of efflux by CCCP brought
MICs down to a level similar to that observed for
S. flexneri 000784, which had a single mutation in
GyrA (Ser83Leu). These data suggested that the
Ser83Leu substitution in GyrA had the greatest
impact on MICs among the target mutations. It
has been shown that the loss of multidrug efflux
can neutralize the resistance contributed by alter-
ation of the target site in E. coli, Salmonella
typhimurium and Pseudomonas aeruginosa [5–7,23].
There was a clear relationship between the
increased expression of genes for efflux pumps
and the resistance to fluoroquinolones in S. flexneri
021787. Expression of tolC (encoding an RND
transporter), mdfA (encoding an MFS transporter)
and ydhE (encoding a MATE transporter) was
induced in the presence of ciprofloxacin. This
observation suggested that these transporters
could accumulate at a low concentration of cipro-
floxacin, leading to more strongly reduced suscep-
tibility. The fluoroquinolone efflux of E. coli is
mainlymediated by acrAB and tolC [24,25]. Expres-
sion of acrAB is primarily regulated by the acrR
repressor gene and the positive regulator marA,
which can also enhance expression of tolC [26–28].
Mutations in acrR and ⁄ or marAmay elevate efflux
pump gene expression and thus increase the
resistance to fluoroquinolones [28]. However,
S. flexneri 021895 produced a lower amount of
transporters and showed increased sensitivity to
ciprofloxacin relative to S. flexneri 021787. This
observation suggested that an active efflux system
contributed more to resistance against ciprofloxa-
cin thanmutations in the target sites. In conclusion,
S. flexneri 021787 and S. flexneri 021895 demon-
strated chromosome-mediated resistance to fluor-
oquinolones, and both isolates carriedmutations in
gyrA and parC while at the same time producing
increased levels of efflux pump transporters.
In recent studies, qnrA, qnrB and qnrS, as well
as aac(6¢)Ib-cr, were shown to be related to
plasmid-mediated quinolone resistance [29].
Both S. flexneri 021787 and S. flexneri 021895
possessed only qnrS, and further studies need
to be performed to determine whether the
expression of qnrS contributes to fluoroquino-
lone resistance.
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